Diamonds and Dogs
7/11/17
Arena Pharmaceuticals (ARNA) jumped nearly 50% thanks to positive data for a lung cancer drug. Arena's experimental drug met its primary goal in a Phase II study for lung disease. One analyst reiterated an Outperform rating on the stock and raising their price target to $53:
Shares of Blue Apron (APRN) are feeling blue. The well-known meal delivery company is down 7% following a downgrade with a price target or $2 or 72% below current levels. Blue Apron probably never should've come public. Its IPO price started in the $15 to $17 range, opening at $10 on June 29th and has only gone lower.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.